Alkermes plc.
Alkermes presented data showing Lybalvi (olanzapine/samidorphan) reduced hospital and emergency visits in schizophrenia and bipolar I patients with alcohol use disorder, according to Hemangi Panchmatia. Long-term data showed stable metabolic parameters and better adherence. Separately, aripiprazole lauroxil demonstrated symptom reductions and a favorable adverse event profile, per Dr. McGrory.
Alkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.
Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ALKS (Alkermes plc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ALKS coverage spans technology, corporate actions and financial news.
In the last 30 days, ALKS insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($181K). The most active reporter was Gaffin David Joseph, EVP, CLO, Alkermes, Inc., with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive clinical real‑world evidence may improve market perception of Alkermes' products.
Early efficacy signals may drive speculative interest, but lack of statistical significance limits immediate trade impact.
Analyst upgrade and positive trial data could lift the stock toward the new target.
Positive early‑stage data may boost investor optimism and drive short‑term price appreciation as the program advances to Phase 2.
The upgraded target may prompt short-term buying pressure as traders adjust positions to the higher upside expectation.
AlphAI scores every news story that mentions ALKS with an AI model for sentiment and relevance, and aggregates insider trades from Alkermes plc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alkermes presented data showing Lybalvi (olanzapine/samidorphan) reduced hospital and emergency visits in schizophrenia and bipolar I patients with alcohol use disorder, according to Hemangi Panchmatia. Long-term data showed stable metabolic parameters and better adherence. Separately, aripiprazole lauroxil demonstrated symptom reductions and a favorable adverse event profile, per Dr. McGrory.
1 min readAlkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.
2 min readGoldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.
2 min readAlkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.
3 min readRBC Capital reiterated an Outperform rating on Alkermes with a $56 price target, implying a 26.8% upside from the Sep 21 close of $44.18. The firm cited the company's commitment to profitability, strong product reception, and encouraging clinical data for its narcolepsy treatment.
1 min readAlkermes' ALKS 7290 showed early efficacy in ADHD. J&J's Caplyta reduced bipolar mania symptoms. Novo Nordisk's CagriSema outperformed Lilly's tirzepatide in weight loss. Novo shares fell on investor day.
2 min readAlkermes (ALKS) stock rose Monday after its orexin-modulating drug, ALKS7290, showed initial positive results in adults with ADHD. The drug targets orexin, a brain chemical linked to wakefulness, previously studied for insomnia and narcolepsy. This marks the first potential breakthrough in ADHD treatment using this approach.
1 min readAlkermes plc (ALKS) rose 6.5% after reporting positive phase 1b trial results for ALKS 7290, an ADHD drug. The study showed clinically meaningful improvements in adult ADHD symptoms with no serious adverse events. A phase 2 trial is ongoing, with data expected in 2027.
2 min readAlkermes plc. (ALKS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy,+1 781 609 6419 Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD
2 min readAlkermes plc. (ALKS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors DUBLIN, Sept. 16, 2026 — Alkermes plc (Nasdaq: ALKS) today announced the appointment of a ne
1 min read
